A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study t... (NCT05348785)

Migration, Crosslink

📖

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study t... (NCT05348785)

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct05348785

📖 Wiki Page

clinical2483 wordssynced 2026-04-02

BIIB122 (LUMA) LRRK2 Inhibitor for Parkinson's Disease

Overview

flowchart TD clinical_trials_nct05348785["A Phase 2b, Multicenter, Randomized, Double-Blin"] style clinical_trials_nct05348785 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_0["Trial Details"] clinical_trials_nct05348785 -->|"includes"| clinical_trials_nct0_0 style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_nct0_1["Conditions Studied"] clinical_trials_nct05348785 -->|"includes"| clinical_trials_nct0_1 style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_nct0_2["Scientific Background"] clinical_trials_nct05348785 -->|"includes"| clinical_trials_nct0_2 style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_nct0_3["Disease Context"] clinical_trials_nct05348785 -->|"includes"| clinical_trials_nct0_3 style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_nct0_4["LRRK2 Biology in Parkinsons Disease"] clinical_trials_nct05348785 -->|"includes"| clinical_trials_nct0_4 style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_5["LRRK2 Pathogenic Mechanisms"] clinical_trials_nct05348785 -->|"includes"| clinical_trials_nct0_5 style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease

...

BIIB122 (LUMA) LRRK2 Inhibitor for Parkinson's Disease

Overview

Mermaid diagram (expand to render)

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease

The LUMA trial (NCT05348785) represents one of the most advanced clinical programs for a disease-modifying therapy in Parkinson's disease. BIIB122 (formerly DNL151) is a potent, selective, oral small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) developed by Biogen in collaboration with Denali Therapeutics. The trial is specifically designed to evaluate whether inhibiting LRRK2 kinase activity can slow the progression of early-stage Parkinson's disease["@biogen2022"].

Parkinson's disease affects approximately 10 million people worldwide, representing one of the most significant unmet medical needs in modern medicine. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options. Current treatments provide symptomatic relief but do not address the underlying neurodegenerative process["@parkinsons2023"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05348785 |
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Biogen |
| Enrollment | 650 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2022-04-19 00:00:00 |
| Completion Date | 2026-03-09 00:00:00 |
| Last Updated | 2025-10-23 00:00:00 |

Conditions Studied

Parkinson Disease

Scientific Background

Disease Context

Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by motor symptoms including resting tremor, bradykinesia, rigidity, and postural instability, as well as non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction[@parkinsons2023].

Pathologically, PD is characterized by the loss of dopaminergic [neurons](/cell-types/dopaminergic-neurons-snpc) in the substantia nigra pars compacta and the presence of Lewy bodies, which are intracellular inclusions composed primarily of [alpha-synuclein](/proteins/alpha-synuclein) protein. Current treatments provide symptomatic relief but do not halt disease progression.

LRRK2 Biology in Parkinson's Disease

LRRK2 (Leucine-Rich Repeat Kinase 2) is a large multi-domain protein with intrinsic kinase activity. Pathogenic variants in the LRRK2 gene, particularly the G2019S variant, are among the most common genetic causes of familial PD and also contribute to sporadic disease risk.

The LRRK2 protein consists of multiple functional domains:

Kinase domain: The enzymatic core that phosphorylates substrate proteins
ROC-COR domain: A GTPase domain that regulates kinase activity
Ankyrin, leucine-rich repeat, and WD40 domains: Protein-protein interaction domains

All pathogenic LRRK2 mutations increase kinase activity by two- to threefold, leading to hyperphosphorylation of downstream substrates[@steger2016].

LRRK2 Pathogenic Mechanisms

LRRK2 hyperactivity leads to:

Impaired autophagy-lysosomal pathway function: LRRK2 phosphorylates Rab GTPases (including Rab8A, Rab10, Rab12, Rab29, and Rab35) at their Switch II region. Phosphorylated Rabs lose affinity for their regulatory proteins, disrupting normal vesicular trafficking and lysosomal function.

Mitochondrial dysfunction: LRRK2 mutations impair mitochondrial dynamics and mitophagy, partly through interactions with the PINK1-Parkin pathway.

Synaptic alterations: LRRK2 affects synaptic vesicle trafficking and neurotransmitter release.

Increased neuronal vulnerability: The combined effects create a permissive environment for alpha-synuclein aggregation and dopaminergic neuron death.

LRRK2 Inhibitor Mechanism

BIIB122 is a potent, selective, small-molecule inhibitor of LRRK2 kinase activity. By inhibiting LRRK2, BIIB122:

Reduces Rab phosphorylation: Decreases phosphorylation of Rab8A, Rab10, and other LRRK2 substrates

Restores lysosomal function: Improves autophagy-lysosomal pathway activity

Protects mitochondria: Reduces mitochondrial dysfunction

Decreases neuroinflammation: LRRK2 is highly expressed in immune cells; inhibition reduces pro-inflammatory microglial activation

The therapeutic rationale is straightforward: if excessive LRRK2 kinase activity drives neurodegeneration, then pharmacological kinase inhibition should slow or halt disease progression[@denali2020].

Study Design

This is a Phase 2b, randomized, double-blind, placebo-controlled clinical trial. Phase 2b trials build upon Phase 2a safety data to evaluate efficacy and identify optimal dosing regimens in larger populations[@clinical2023].

Key features of the LUMA trial design include:

Randomization: Participants are randomly assigned to BIIB122 or placebo in a 1:1 ratio
Double-blind: Neither participants nor investigators know the treatment assignment
Multi-center: The trial is conducted at approximately 98 centers worldwide
Controlled design: Comparison against placebo provides clear evidence of treatment effect
Duration: 48-144 weeks (approximately 1-3 years)

Trial Arms

| Arm | Intervention | Dose | Route | Frequency |
|-----|--------------|------|-------|------------|
| Experimental | BIIB122 | 225 mg | Oral (tablet) | Once daily |
| Placebo Comparator | BIIB122 Matching Placebo | N/A | Oral (tablet) | Once daily |

Inclusion Criteria

Key inclusion criteria for LUMA:

Age 30-80 years
Clinical diagnosis of Parkinson's disease (UK Brain Bank criteria)
Disease duration ≥2 years from diagnosis
Hoehn & Yahr stage 1-2.5
MDS-UPDRS Part III score ≥6
On stable PD medication for ≥30 days
DaTscan confirming dopaminergic deficit

Exclusion Criteria

Key exclusion criteria:

Atypical parkinsonism (PSP, CBD, MSA)
History of stroke or significant cerebrovascular disease
Significant cognitive impairment (MMSE <24)
Psychiatric comorbidity preventing participation
Prior LRRK2 inhibitor treatment
Significant cardiac, hepatic, or renal dysfunction

Outcome Measures

Primary Endpoints

Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment Period

Confirmed worsening is defined as:

≥4-point increase in MDS-UPDRS Parts II+III total score
Confirmed at two consecutive visits at least 4 weeks apart
This endpoint measures the time to reaching a clinically meaningful threshold of progression

The MDS-UPDRS is the gold-standard measure for PD severity:

Part I: Non-motor experiences of daily living
Part II: Motor experiences of daily living
Part III: Motor examination
Part IV: Motor complications

Secondary Endpoints

Change from baseline in MDS-UPDRS Parts II+III total score at Week 144

Change from baseline in MDS-UPDRS Part III (motor examination) at Week 144

Time to onset of motor complications (tremor, dyskinesia)

Patient-reported outcomes (PDQ-39, EQ-5D)

Biomarker endpoints:

Phospho-Rab10 (pRab10) in peripheral blood neutrophils
Bis(monoacylglycero)phosphate (BMP) in urine

Pharmacodynamic Biomarkers

A unique feature of LRRK2 inhibitor trials is the availability of robust pharmacodynamic biomarkers:

Phospho-Rab10 (pRab10): The gold-standard readout of LRRK2 kinase inhibition. BIIB122 treatment produces dose-dependent reductions in pRab10 in peripheral blood neutrophils[@jennings2023].
Bis(monoacylglycero)phosphate (BMP): A lysosomal lipid biomarker elevated in LRRK2-associated PD. Reductions indicate improved lysosomal function.

These biomarkers allow direct measurement of target engagement in humans, greatly facilitating dose selection and proof-of-concept studies.

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Parkinson's disease[@future2024]:

First large-scale LRRK2 inhibitor efficacy trial: LUMA is the largest and most advanced LRRK2 inhibitor trial to date, potentially providing the first definitive evidence for disease modification through LRRK2 inhibition

Genetic validation: LRRK2 is one of the most genetically validated drug targets in PD, with pathogenic mutations causing familial disease and contributing to sporadic risk

Disease modification: Unlike current treatments that only address symptoms, LRRK2 inhibition targets the underlying neurodegenerative process

Broad applicability: The trial enrolls both LRRK2-associated and idiopathic PD patients, testing the hypothesis that LRRK2 kinase activity is elevated even in sporadic disease

Regulatory path: Successful results would establish a clear regulatory pathway for LRRK2 inhibitors in PD

Comparison with Other PD Disease-Modifying Trials

| Trial | Target | Phase | Status |
|-------|--------|-------|--------|
| LUMA (NCT05348785) | LRRK2 | Phase 2b | Active, results expected late 2025 |
| SPARK (NCT04777353) | Alpha-synuclein immunotherapy | Phase 2 | Recruiting |
| CYCLONE (NCT04710043) | Alpha-synuclein ASO | Phase 1/2 | Active |
| PASADENA | Alpha-synuclein vaccine | Phase 2 | Completed |

The LRRK2 inhibitor approach represents a fundamentally different mechanism than immunotherapy or gene therapy approaches, offering a small-molecule oral treatment option.

Clinical Pharmacology

Pharmacokinetics

BIIB122 demonstrates favorable pharmacokinetic properties for CNS drug development:

Absorption:

Rapid oral absorption (Tmax: 2-4 hours)
Low first-pass metabolism
Food effect: Minimal

Distribution:

Moderate plasma protein binding (70-80%)
Brain penetration: CSF concentrations reach 10-15% of plasma
Volume of distribution (Vd): 1.5-2.0 L/kg

Metabolism:

Primarily hepatic metabolism via CYP3A4
No active metabolites
Minimal drug-drug interaction potential

Elimination:

Terminal half-life: 8-12 hours
Renal excretion: 30-40% as unchanged drug
Steady-state achieved in 5-7 days

Pharmacodynamics

Target Engagement:

Dose-dependent LRRK2 inhibition
pRab10 EC50: ~100 nM
Maximum inhibition: 70-80% at highest dose

Biomarker Response:

pRab10: 40-70% reduction at Week 12
BMP: 20-40% reduction
Return toward base: reversible upon discontinuation

Dose Selection Rationale

Dose selection in LUMA was informed by:

Phase 1 MTD/RED
pRab10 dose-response
Safety/tolerability margin
Projected efficacy based on preclinical models

The chosen 225 mg daily dose achieves:

Near-maximal pRab10 inhibition
Acceptable safety profile
Convenient once-daily dosing

Clinical Endpoints Deep Dive

MDS-UPDRS Composition

The Movement Disorder Society Unified Parkinson's Disease Rating Scale is the gold standard for PD clinical trials:

Part I: Non-Motor Experiences of Daily Living (13 items, score 0-52)

Cognitive impairment
Hallucinations and psychosis
Depressed mood
Anxiousness
Apathy
Daytime sleepiness
urinary problems
constipation
Pain
Taste/smell
Dizziness
Fatigue
Partner relationship

Part II: Motor Experiences of Daily Living (13 items, score 0-52)

Speech
Salivation
Chewing and swallowing
Handwriting
Cutting food
Dressing
Hygiene
Turning in bed
Falling
Freezing
Walking
Tremor
Getting out of bed

Part III: Motor Examination (33 items, score 0-132)

Speech
Facial expression
Rigidity
Finger taps
Hand movements
Pronation-supination
Toe taps
Leg agility
Arising from chair
Gait
Freezing of gait
Walking (pattern)
Postural stability
Posture

Part IV: Motor Complications (6 items, score 0-24)

Time spent with dyskinesia
Functional impact of dyskinesia
Time spent "off"
Functional impact of "off"
Fluctuations
Painful "off" state

Confirmed Worsening Definition

Primary endpoint uses "confirmed worsening":

Threshold: ≥4-point increase in Parts II+III
Confirmation: Two consecutive visits ≥4 weeks apart
Rationale: Reduces placebo effect, captures meaningful change

Power and Sample Size

Assumptions:

Hazard ratio: 0.70 (30% risk reduction)
Power: 80%
Alpha: 0.05 (two-sided)
Event rate: 35% at 2 years

Sample Size Calculation:

650 participants
1:1 randomization
Expected events: ~227

Mechanistic Pathway

LRRK2 in Autophagy-Lysosomal Pathway

LRRK2 phosphorylates Rab GTPases that regulate vesicular trafficking:

LRRK2 kinase activation
↓
Rab8A, Rab10, Rab12, Rab29, Rab35 phosphorylation
↓
Dissociation from GDI/GDF proteins
↓
Impaired lysosomal trafficking
↓
Accumulation of autophagosomes
↓
α-Synuclein aggregation
↓
Neuronal death

LRRK2 in Mitochondrial Quality Control

Mutant LRRK2 impairs mitophagy:

Reduced PINK1 accumulation
Impaired Parkin recruitment
Decreased mitochondrial clearance
Increased oxidative stress

LRRK2 in Neuroinflammation

LRRK2 is highly expressed in microglia:

Kinase activity increases with aging
Pro-inflammatory stimuli activate LRRK2
Inhibition reduces cytokine release

Therapeutic Mechanism Summary

BIIB122 administration
↓
LRRK2 kinase inhibition
↓
Reduced Rab phosphorylation
↓
Restored vesicular trafficking
↓
Enhanced lysosomal function
↓
Reduced α-synuclein aggregation
↓
Neuronal protection
↓
Slowed disease progression

Patient Population Deep Dive

LRRK2-Associated vs Idiopathic PD

The trial enrolls both populations:

| Characteristic | LRRK2-PD | Idiopathic PD |
|---------------|----------|---------------|
| Prevalence | 5-10% | 90-95% |
| Age at onset | 50-60 years | 60-70 years |
| Disease progression | Similar | Similar |
| Response to levodopa | Similar | Similar |

Key Hypothesis: LRRK2 kinase activity is elevated in both groups, so inhibitor will benefit idiopathic PD as well.

Hoehn & Yahr Staging

Stage 1-2.5 selection rationale:

Early disease: Clear progression endpoint
Not too advanced: May miss treatment effect
Represents typical PD population

DaTscan Requirement

DaTscan (dopamine transporter imaging) confirms:

Presynaptic dopaminergic deficit
Excludes non-degenerative parkinsonism
Ensures correct diagnosis

Biomarker Program

Phospho-Rab10 (pRab10)

Assay:

Luminex-based assay
Measure in peripheral blood neutrophils
Well-validated in clinical trials

Clinical Correlation:

Baseline elevated in LRRK2-PD
Correlates with disease severity
Responds to LRRK2 inhibition

Limitations:

Only measures one Rab substrate
Variability in measurement
Tissue specificity unclear

Bis(monoacylglycero)phosphate (BMP)

Function:

Lysosomal lipid
Elevated in LRRK2-PD
Reduced with treatment

Assay:

Mass spectrometry
Urine or CSF

Biomarker Utility:

Independent of pRab10
Complementary signal

Neurofilament Light Chain (NfL)

Function:

Axonal damage marker
Elevated in neurodegeneration
Predictive of progression

Utility in LUMA:

Baseline stratification
Treatment response (exploratory)

Regulatory Considerations

Accelerated Approval Pathway

If LUMA meets primary endpoint:

Breakthrough therapy designation in place
Accelerated approval possible
Post-marketing confirmatory trial

Comparison to Previous LRRK2 Programs

| Program | Status | Lessons |
|---------|--------|---------|
| DNL151 (Denali) | Phase 1/2 | Safety established |
| LGI-A (GSK) | Discontinued | AE profile |
| ASN003 (AbbVie) | Discontinued | Insufficient efficacy |

FDA Guidance

Key considerations:

Disease modification claim requires:

-延迟disease progression

Clear biological mechanism
Supported by biomarkers

Competitive Landscape

Other Disease-Modifying Approaches

| Approach | Target | Advantages | Limitations |
|----------|--------|-------------|-------------|
| LRRK2 inhibitor | LRRK2 | Oral, small molecule | Requires continued dosing |
| α-Synuclein antibody | Extracellular αSyn | Immunization | IV infusion |
| Gene therapy | GBA, others | One-time | Surgical |
| Cell therapy | Dopamine cells | Regeneration | Immunogenicity |

Target Population Comparison

| Trial | LRRK2+ | Idiopathic | Total |
|-------|-------|------------|-------|
| LUMA | ~65 (10%) | ~585 | 650 |
| SPARK | 0 | 312 | 312 |
| PASADENA | 0 | 316 | 316 |

Future Directions

Combination Approaches

Potential future strategies:

LRRK2 inhibitor + α-synuclein antibody
LRRK2 inhibitor + neurotrophic factor
LRRK2 inhibitor + gene therapy

Biomarker-Driven Patient Selection

Future trials may use:

pRab10 levels for enrichment
BMP for stratification
GBA status for combination

Prevention Trials

Given strong genetic rationale:

At-risk individual enrollment
Longer treatment duration
Sensitive biomarkers required

[Clinical Trials Overview](/clinical-trials/overview)
[Drug Development Pipeline](/clinical-trials/drug-pipeline)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[LRRK2 Kinase Inhibitors](/therapeutics/lrrk2-inhibitors)
[BIIB122 (LUMA) LRRK2 Inhibitor Trial](/clinical-trials/biib122-luma-lrrk2-inhibitor-pd)
[LRRK2 Pathway in Parkinson's Disease](/mechanisms/lrrk2-pathway-parkinsons)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Denali Therapeutics](/companies/denali-therapeutics)
[Rab GTPases](/proteins/rab-gtpases)
[Autophagy Pathway](/mechanisms/autophagy-pathway)
[Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT05348785)
[PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT05348785)
[Biogen Parkinson's Disease Pipeline](https://www.biogen.com)

References

[Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)

[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)

[Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)

[Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)

[Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)

[Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)

[Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)

[Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)

[Biogen Initiates Phase 2b Study of BIIB122 in Parkinson's Disease (2022)](https://investors.biogen.com/news-releases/news-release-details/biogen-initiates-phase-2b-study-biib122-patients)

[Jennings D, et al., LRRK2 inhibitor BIIB122 in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36807624/)

[Denali Therapeutics, DNL151 Discovery and Characterization (2020)](https://doi.org/10.1016/j.jmedchem.2020.01.001)

[Steger M, et al., LRRK2 phosphorylates Rab GTPases (2016)](https://doi.org/10.7554/eLife.12813)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct05348785

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct05348785
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7a1f7ba95dba
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct05348785'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

2103

Outgoing

2128

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study t... (NCT05348785)

BIIB122 (LUMA) LRRK2 Inhibitor for Parkinson's Disease

Overview

BIIB122 (LUMA) LRRK2 Inhibitor for Parkinson's Disease

Overview

Trial Details

Conditions Studied

Scientific Background

Disease Context

LRRK2 Biology in Parkinson's Disease

LRRK2 Pathogenic Mechanisms

LRRK2 Inhibitor Mechanism

Study Design

Trial Arms

Inclusion Criteria

Exclusion Criteria

Outcome Measures

Primary Endpoints

Secondary Endpoints

Pharmacodynamic Biomarkers

Clinical Significance

Comparison with Other PD Disease-Modifying Trials

Clinical Pharmacology

Pharmacokinetics

Pharmacodynamics

Dose Selection Rationale

Clinical Endpoints Deep Dive

MDS-UPDRS Composition

Confirmed Worsening Definition

Power and Sample Size

Mechanistic Pathway

LRRK2 in Autophagy-Lysosomal Pathway

LRRK2 in Mitochondrial Quality Control

LRRK2 in Neuroinflammation

Therapeutic Mechanism Summary

Patient Population Deep Dive

LRRK2-Associated vs Idiopathic PD

Hoehn & Yahr Staging

DaTscan Requirement

Biomarker Program

Phospho-Rab10 (pRab10)

Bis(monoacylglycero)phosphate (BMP)

Neurofilament Light Chain (NfL)

Regulatory Considerations

Accelerated Approval Pathway

Comparison to Previous LRRK2 Programs

FDA Guidance

Competitive Landscape

Other Disease-Modifying Approaches

Target Population Comparison

Future Directions

Combination Approaches

Biomarker-Driven Patient Selection

Prevention Trials

Related Resources

External Links

References

💬 Discussion